Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc receives positive CVMP opinion for Strangvac, a vaccine against equine strangles, in the EU
Stockholm, June 17, 2021 – Intervacc AB (“Intervacc”) announced today that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac® within the EU....Report from Annual General Meeting in Intervacc
Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 9 June 2021, at which the following resolutions were made. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherings, the Annual...Intervacc and the Karolinska Institutet sign a multi-year contract for the development of innovative animal health vaccines
Stockholm May 28, 2021 – Intervacc AB (publ) and the Karolinska Institute, KI, announce today that they have extended the contract for the development of a new generation of animal health vaccines using recombinant proteins. The three-year contract means that...Interim report January – March 2021
The period in summary First quarter January 1 – March 31, 2021 The regulatory process for the Company’s Marketing Authorization Application (MAA) for Strangvac in Europe has proceeded according to plan. On January 12th Intervacc submitted the responses to the Day 120...Notice of annual general meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 9 June 2021. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on...Nyhetstjänster
